North America Sickle Cell Disease Market, by Disease Type (Sickle Cell Anemia, Sickle Beta Thalassemia, and Sickle Hemoglobin C Disease), by Drug Type (Hydroxyurea, L-glutamine, Crizanlizumab, Pain-relievers, Voxelotor, and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (U.S and Canada), is estimated to be valued at US$ 770.5 Million in 2021 and is expected to exhibit a CAGR of 16.2% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
The key players operating in the market are focusing on the development of gene therapies for the treatment of sickle cell disease, which is expected to offer a lucrative opportunity for the market players to launch novel product in the market. For instance, in March 2020, Agios Pharmaceuticals, Inc., a biotechnology company announced that the company had received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients suffering from sickle cell disease.
North America Sickle Cell Disease Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has negatively affected various industries globally. The COVID-19 pandemic caused major disruptions to clinical trial executions in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced disturbances, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, Contract Research Organizations, and other organizations that support drug development shifted to remote working environments. Furthermore, the U.S. FDA guidance (July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits or include novel ways for conducting clinical trials in place of current protocols. Therefore, there are now more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other nontraditional approaches that do not involve in-person visits. Moreover, regulatory bodies such as the U.S. Food Drug and Administration are focusing on imposing the guidelines to prevent the spread of the COVID-19 infection while conducting clinical trials on participants/subjects.
Browse 17 Market Data Tables and 25 Figures spread through 166 Pages and in-depth TOC on “North America Sickle Cell Disease Market”- Forecast to 2028, North America Sickle Cell Disease Market, by Disease Type (Sickle Cell Anemia, Sickle Beta Thalassemia, and Sickle Hemoglobin C Disease), by Drug Type (Hydroxyurea, L-glutamine, Crizanlizumab, Pain-relievers, Voxelotor, and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (U.S. and Canada)
To know the latest trends and insights prevalent in the North America Sickle Cell Disease Market, click the link below:
The increasing product approvals by key players for the treatment of sickle cell disease is expected to drive the growth of the North America sickle cell disease market over the forecast period. For instance, in September 2020, Bristol Myers Squibb Company, a pharmaceutical company, and Acceleron Pharma, a pharmaceutical company, collaboratively received the Health Canada approval for Reblozyl (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anaemia associated with beta(β)-thalassemia.
Key Takeaways of the North America Sickle Cell Disease Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.